A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke (MILESTONE sm) "MILESTONEā "
Completed
Phase 3 ResultsSummary of Purpose
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 11 January 2018.
1 Dec 2014 | 20 Oct 2014 | 1 Sep 2016 | 1 Oct 2016 | 1 Sep 2017 | 22 Sep 2017 |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
- US Call Center #
1-877-721-3493
View Trial Locations
Recruitment
- Enrollment: 377
- Gender: All
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 174 locations, 2 countries
Principal Investigators
- Enrique Carrazana, MD
Acorda Therapeutics
- Holly Roberts, MD
Acorda Therapeutics